Information Provided By: 
Fly News Breaks for July 30, 2018
CHE
Jul 30, 2018 | 07:31 EDT
RBC Capital analyst Frank Morgan raised his price target on Chemed to $321 after its Q2 earnings beat, saying the company continued its strong census trends at VITAS and also posted solid core growth at Roto-Rooter. Morgan also keeps his Sector Perform rating on Chemed, adding that even though the company has solid business fundamentals, he is concerned with its capital deployment as its "elevated" share price will make buybacks "tricky".
News For CHE From the Last 2 Days
There are no results for your query CHE
